New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
16:17 EDTCERUCerulean reports Q2 EPS (44c), consensus (36c)
Reports Q2 revenue $33K. As of June 30, Cerulean had cash and cash equivalents of $64.3M. Cerulean estimates that its current cash and cash equivalents will allow it to fund several ongoing single-arm clinical trials of CRLX101, an ongoing randomized Phase 2 clinical trial of CRLX101, and a planned Phase 1 trial of CRLX301. CEO Oliver Fetzer said, "We anticipate announcing data from two ongoing single-arm CRLX101 trials in the first quarter of 2015, data from an ongoing randomized CRLX101 trial by the end of 2015, and data from a planned Phase 1 CRLX301 trial by the end of 2015."
News For CERU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 1, 2015
08:47 EDTCERUCerulean data positive, says Roth Capital
Roth Capital says that data generated from the combination of Cerulean's CRLX101 and Avastin in ovarian cancer patients "compares favorably" with Avastin taken alone. The firm thinks that the addition of CRLX101 could enhance Avastin+chemo regimens. It keeps a $9 price target and Buy rating on the shares.
September 30, 2015
07:08 EDTCERUCerulean said CRLX101 advances to second stage of Phase 2 clinical trial
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use